ViaCyte, Inc. | Date: 2016-10-28
The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.
ViaCyte, Inc. | Date: 2016-11-11
Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.
ViaCyte, Inc. | Date: 2017-02-13
Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
ViaCyte, Inc. | Date: 2017-02-22
Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-15-2015 | Award Amount: 6.80M | Year: 2015
Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulins homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases have shown proof-of-principle but also the need for developing a large-scale source for therapeutic cells. Our objective is to generate a functional beta cell mass by stem cell-derived implants in diabetes patients. A combined preclinical and clinical project will search recipient and implant conditions for formation and maturation of beta cells in subcutaneous implants of device-encapsulated pancreatic endodermal cells that are derived from human embryonic stem cells (hu-ES) and manufactured for clinical studies. We collected preclinical evidence for the therapeutic potential of this implant from comparison with clinically used human beta cell grafts. State-of-the art methods and markers have been developed to investigate the biology of implants and to monitor host immune and innate reactivity. This approach helps understand the basis for metabolic outcome and identify targets for improvement. Pilot studies examine the influence of the (auto)immune status of the patients. Data will determine transition to clinical efficacy studies, or indicate the need for further laboratory development. Implants in preclinical models will guide modifications in clinical protocols, and explore the biologic properties of grafts derived from human induced pluripotent stem cell (iPSc) as can also be prepared from diabetes patients. Our consortium joins innovating cells, methods, markers and minds in a unique combination of expert clinical, academic and industry activities that need each other to make progress in an ambitious program.
ViaCyte, Inc. | Date: 2016-03-09
Disclosed herein are methods for generating endoderm lineage type cells derived from human pluripotent cells, such as human embryonic stem cells, by using various agents including, but not limited to, GDF8, GDF11 and GSK-3beta inhibitors. Also disclosed herein are endoderm lineage cell populations or compositions, such as populations or compositions comprising definitive endoderm and/or other definitive endoderm-derived cell types.
ViaCyte, Inc. | Date: 2016-06-03
Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
ViaCyte, Inc. | Date: 2016-08-22
The present invention provides, in at least one embodiment, a loading device, system and method that loads aggregate cells into an encapsulation device for implanting into a patient. The loading system uses negative pressure from a low pressure pump in a closed system to improve safety and cell viability while allowing for even loading of the encapsulation device.
ViaCyte, Inc. | Date: 2016-10-11
Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.
ViaCyte, Inc. | Date: 2016-06-10
The present invention relates to compositions and methods for inhibiting or suppressing undifferentiated or pluripotent stem cell growth and proliferation in a differentiated or differentiating cell population or culture.